Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "Harrow, Inc.") for the reporting period of June 14, 2016. The filing addresses the termination of a material definitive agreement with Urigen Pharmaceuticals, Inc. regarding a license for the URG101 product, a compounded formulation for lower urinary tract disorders.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to a legal dispute: Urigen has asserted unpaid royalties totaling $698,288 in a cross-complaint for breach of contract.
Material Changes
- Termination of License Agreement: On June 14, 2016, Urigen elected to terminate the License Agreement entered into in October 2014.
- Legal Proceedings: Imprimis filed a civil action in December 2015 alleging material failures in Urigen's representations. Urigen filed a cross-complaint in April 2016 seeking $698,288 in unpaid royalties and cancellation of the agreement. Imprimis filed a separate complaint in May 2016 seeking a declaratory judgment of invalidity for the underlying patent (Patent '039).
Outlook, Risks, and Management Commentary
Management believes it will prevail in its case for the invalidity of Patent '039 and intends to continue serving customers prescribed compounded drugs containing heparin and alkalinized lidocaine despite the termination. The Company has made accruals related to the License Agreement but states that the outcome of the legal claims may have a material effect on its consolidated financial position and results of operations that differ from those accruals. The specific amount of this potential impact cannot be reasonably estimated at this time.
Investor Verification Checklist
- Verify the status of the civil action in San Diego Superior Court and the declaratory judgment complaint in the U.S. District Court for the Southern District of California.
- Confirm the validity of the $698,288 royalty claim asserted by Urigen.
- Assess the Company's ability to continue selling URG101 or similar compounded formulations without the terminated license.
- Review the full text of the License Agreement (Exhibit 10.1 to the October 29, 2014 Form 8-K) for specific termination clauses and liability caps.